Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Key Decisions in HIV Care: Data on Long-Acting Injectable PrEP

Source: Key Decisions in HIV Care
Listen as Jason Schafer, PharmD, MPH, shares the latest data to support long-acting PrEP, including efficacy and safety data from the major clinical trials that led to the approval of cabotegravir for PrEP.
person default
Jason Schafer, PharmD, MPH
Released: March 14, 2022

In this episode, Jason Schafer, PharmD, MPH, explores the data for long-acting injectable pre-exposure prophylaxis (PrEP).

Listen as he gives his perspectives on the:

  • PrEP pipeline and the importance of having options for patients with differing preferences
  • FDA approval of long-acting cabotegravir for PrEP
  • HPTN 083 and 084 studies of long-acting cabotegravir for PrEP compared with oral emtricitabine/tenofovir disoproxil fumarate
  • Safety data on long-acting cabotegravir for PrEP
  • CDC recommendations on the management of injection-site reactions with cabotegravir for PrEP

Acknowledgements

Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Information on this Educational Activity

Faculty

Jason Schafer, PharmD, MPH

Professor and Vice Chair
Jefferson College of Pharmacy
Thomas Jefferson University
Philadelphia, Pennsylvania

Jason Schafer, MD, MPH, has disclosed that he has received funds for research support from Gilead Sciences and Merck and consulting fees from Merck and ViiV.

Program Medium

This program has been made available online.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings